

Cite this: *Org. Biomol. Chem.*, 2011, **9**, 7411

www.rsc.org/obc

PAPER

Stereoselective vinylogous Mannich reaction of 2-trimethylsilyloxyfuran with *N*-gulosyl nitrones†

Osamu Tamura,^{*a} Kodai Takeda,^b Naka Mita,^c Masanori Sakamoto,^c Iwao Okamoto,^a Nobuyoshi Morita^a and Hiroyuki Ishibashi^b

Received 2nd July 2011, Accepted 5th August 2011


DOI: 10.1039/c1ob06067h

Stereoselective vinylogous Mannich reaction of 2-trimethylsilyloxyfuran with *L*-gulose-derived chiral nitrones in the presence of a catalytic amount of trimethylsilyl trifluoromethanesulfonate was investigated. The selectivity was strongly influenced by the bulkiness of the *C*-substituent of the nitron: for example, *C*-benzyloxymethyl nitron afforded four stereoisomers, whereas bulky *C*-[(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]nitron gave a single stereoisomer. The latter product was elaborated to afford key synthetic intermediates for polyoxin C and dysiherbaine.

Introduction

Nucleophilic addition reaction of dienolates **2** with imines or iminium ions **1** leading to δ -amino α,β -unsaturated carbonyl compounds **3** is known as the vinylogous Mannich reaction,¹ and is useful in the synthesis of nitrogen-containing natural products and related compounds (Scheme 1, equation 1).² In this category, addition reaction of 2-silyloxyfurans to a C–N double bond is very attractive, allowing oxygen functionalities as well as C4-units to be incorporated into nitrogen-containing carbon frameworks.^{3,4}

Enantioselective addition reactions of 2-silyloxyfuran and related compounds have been addressed in recent years,⁴ and recently diastereoselective addition reactions to C–N double bond compounds bearing chiral auxiliaries have been reported.^{3g} Among C–N double bond compounds, nitrones **4** are known to undergo Mannich reaction with 2-silyloxyfuran **5** in the presence of a catalytic amount of TMSOTf to give bicyclic compounds **6** after TBAF treatment of the initial adducts **6** (equation 2).^{5,6} Previously, we described diastereoselective addition reaction of 2-trimethylsilyloxyfuran (**5**) to nitron **8**, which contains a hydroxymethyl group equivalent and an *L*-gulose-derived chiral auxiliary as an *N*-substituent; the resulting adduct was elaborated to afford a synthetic intermediate of polyoxin C.⁷ Herein, we present a full account of that work, including an additional application of the reaction to synthesis of a key synthetic intermediate of dysiherbaine.



Scheme 1 Vinylogous Mannich reactions.

Results and discussion

1. Stereoselective nucleophilic addition of 2-trimethylsilyloxyfuran **5** to *N*-(2,3,5,6-*O*-isopropylidene-*L*-gulosyl)nitrones **8**

For diastereofacially selective 1,3-dipolar cycloaddition or nucleophilic addition of nitrones, protected glycosyl groups, such as mannosyl⁸ and gulosyl groups,^{7,9,10} have been used as *N*-chiral auxiliaries. These groups can be removed under mild acidic conditions, whereas removal of benzyl-type auxiliaries, such as the 1-phenylethyl group, generally requires hydrogenolysis (Fig. 1). Although both mannosyl and gulosyl groups often exhibit high stereoselectivity, we have focused on the gulosyl auxiliary because

^aShowa Pharmaceutical University, Machida, Tokyo 194-8543, Japan. E-mail: tamura@ac.shoyaku.ac.jp; Fax: +81 (0)42 721 1579; Tel: +81 (0)42 721 1578

^bDivision of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa 920-1192, Japan

^cMeiji Pharmaceutical University, Kiyose, Tokyo 204-8588, Japan

† Electronic supplementary information (ESI) available: ¹H and ¹³C NMR spectra. See DOI: 10.1039/c1ob06067h





Fig. 1 Nitrones bearing chiral auxiliaries.

(i) both enantiomers are available and (ii) the stereochemistry of the product can be predicted.^{7,10}

Our investigation began with preparation of four types of L-gulose-derived nitronium **8**. Treatment of oxime **9**, prepared from 2,3:5,6-*O*-isopropylidene-L-gulonolactone in two steps, with aldehydes **10a–d** in the presence of MgSO₄ in CHCl₃ at room temperature gave crystalline nitrones **8a–d** (Scheme 2). Since these nitrones were not very stable, they were used immediately for the next step.





Scheme 2 Synthesis of nitrones **8a–d**.

When nitrones **8a–d** were treated with 2-trimethylsilyloxyfuran (**5**) (1.5 equiv) in the presence of TMSOTf (0.1 equiv) at low temperature, smooth nucleophilic addition to siloxyiminium ion **A** occurred to give butenolides **B** as the initial adducts, and these were further treated with TBAF (0.1 equiv) to afford bicyclic products **11–14** (Scheme 3 and Table 1).

The results, summarized in Table 1, showed that all reactions afforded the adducts **11** as the major products, and nitrones **8** having bulkier substituents exhibited greater stereoselectivity. *C*-Benzyloxymethyl nitronium **8a** gave a 76:13:8:3 mixture of four isomers **11a–14a** (entry 1). Nitronium **8b**, having a triisopropylsilyloxymethyl group as the substituent **R**, afforded a 74:21:5 mixture of three isomers (entry 2). Nitronium **8c** carrying the even bulkier *tert*-butyldiphenylsilyloxymethyl group showed still

Table 1 Addition reaction of nitrones **8a–d** with silyloxyfuran **5**


Entry	Nitronium 8 (R)	Yield (%)	Ratio 11 : (12 + 13 + 14)
1	8a (CH ₂ OBn)	84	76: (13 + 8 + 3)
2	8b (CH ₂ OTIPS)	80	74: (21 + 5)
3	8c (CH ₂ OTBDPS)	80	86: (8 + 6)
4	8d ()	72	>97: <3



Scheme 3 Addition reaction of nitrones **8a–d** with silyloxyfuran **5**.

greater stereoselectivity (entry 3). Finally, nitronium **8d**, bearing the branched 2,2-dimethyldioxolane ring, exclusively afforded **11d**.

The substituent effect on the stereoselectivity of the present addition reaction of nitrones **8** may be explained in terms of the effect of the bulkiness of the substituent **R** on the initially generated siloxyiminium ion **A**. The stereochemistry of the products **11–14** of the reaction of nitronium **8** with 2-trimethylsilyloxyfuran **5** should be determined at the step of the addition reaction of furan **5** to siloxyiminium ion **A**, affording the initial adduct **B** (Schemes 3 and 4). Three types of staggered approach of silyloxyfuran **5** to siloxyiminium ion **A** can be considered (see **C–F** in Scheme 4; for simplicity, only upper-face approaches of silyloxyfuran to siloxyiminium ion **A** are illustrated). Among the three approach routes **C–F**, approach **C** would be more favorable than **D** or **F** because there is less interaction of the furan ring of **5** with substituents of **A**. Approach **C** may be further divided into two transition state models **C**₁ and **C**₂, which give opposite relative stereochemistries. Since the 4-position of furan is apparently bulkier than the 1-position is, the use of nitronium having a sterically more demanding *C*-substituent makes model **C**₂ more favorable than model **C**₁. Transition state **C**₂ should exhibit high diastereofacial selectivity because of the closeness between the 4-position and the chiral auxiliary, whereas both antipodal transition states would be possible in the case of **C**₁. Accordingly, the use of bulky nitrones **8c** and **8d** causes addition reaction of silyloxyfuran **5** to proceed preferentially by way of transition state **C**₂ to afford **11** with good diastereo- and diastereofacial selectivity. It is known that addition reaction of the *N*-benzyl congener **8e** of **8d** with silyloxyfuran **5** in the presence of TMSOTf gives four stereoisomers of adducts with very low stereoselectivity.^{6c} This fact clearly indicates that the stereoselectivity of the present reaction of **8d** arises mainly from the effect of the gulose auxiliary.



2. Synthetic studies of polyoxin C from adducts **11c** and **11d** as intermediates

Thymine and uracil polyoxin Cs (**17a** and **17b**), which are hybrid compounds of nucleosides and α -amino acids, are important as the C-terminal amino acid components of polyoxin J (**15**) and nikkomycin Bz (**16**), which exhibit anti-fungal activity (Fig. 2). Therefore, stereoselective syntheses of the unique amino acids **17** have been intensively investigated.^{3e,11,12} An efficient method for syntheses of polyoxin Cs would be elaboration of dihydroxy lactone **18**,^{12g} and therefore we next examined the synthesis of lactone **18** from adducts **11c** and **11d**, which we obtained






Fig. 2 Structures of polyoxins, nikkomycin Bz, and intermediate **18**.

stereoselectively as described above. For the synthetic study of polyoxin C, stereochemical correlation of adduct **11c** with **11d** was first conducted (Scheme 5). Hydrolytic removal of the sugar auxiliary of adduct **11c** by acid treatment followed by *N*-protection with a Boc group afforded **19**. Similar treatment of adduct **11d** gave diol **20**. Compound **19** was further treated with TBAF under acidic conditions to provide alcohol **21**, which was also obtained by oxidative cleavage of diol **20**, followed by reduction of the resulting aldehyde with zinc borohydride.



Compound **21** was next elaborated to dihydroxylactone **18**,^{12g} a key synthetic intermediate of polyoxin C (Scheme 6). Reductive cleavage of the *N*-*O* bond of compound **21** by heating with $\text{Mo}(\text{CO})_6$ ¹³ in acetonitrile–water and subsequent treatment with 2,2-dimethoxypropane in the presence of PPTS provided *N*,*O*-acetone **22** in 54% yield. Mesylation of the secondary alcohol of **22** induced β -elimination to yield butenolide **23** in 96% yield. Finally, stereoselective dihydroxylation of butenolide **23** was conducted as described in the literature to afford lactone **18**.



Scheme 6 Synthesis of lactone **18**.

3. Synthetic studies of dysiherbaine from adduct **11d**

Dysiherbaine (**24**), isolated from a Micronesian marine sponge *Dysidea herbacea*, is a strong and selective agonist of non-NMDA type glutamate receptors in the central nervous system (Fig. 3).¹⁴ Owing to this remarkable biological activity, considerable efforts have been made to synthesize the natural product, and several total syntheses of **24** have been reported to date.^{15,16} Among them, Hatakeyama's synthesis, in which tricyclic lactone **25** is used as the key synthetic intermediate, seems to be one of the most efficient.^{15c,f,16d} Structural consideration of adduct **11d** showed that the stereochemistry of **11d** is in accordance with that of lactone **25** (compare formula **25** with **11d'**). Thus, we next turned our attention to the transformation of adduct **11d** to lactone **25**.





Fig. 3 Stereochemical accordance of adduct **11d** with lactone **25**.

Elaboration to **25** began with monoprotection of diol **20**, prepared in the synthetic study of polyoxin C, with a TBDPS group, affording **26**, from which the Boc group was removed under acidic conditions to give amino alcohol **27**. The key *N*-methylation was conducted by exposure of **27** to formaldehyde in ethanol, followed by treatment of the resulting mixture of **28** and **29** with triethylsilane and trifluoroacetic acid to provide compound **30** (Scheme 7).¹⁷


The next task was oxazolidinone formation and dihydropyran construction. To this end, phenoxycarbonylation of the secondary hydroxyl group of **30** was first conducted to provide carbonate **31** in 89% yield. When carbonate **31** was exposed to hydrogenolysis conditions, reductive cleavage of the *N*-*O* bond and subsequent ring closure of **32** occurred to give oxazolidinone **33** in 91% yield. Chloromesylation of the secondary hydroxyl group of **33** induced β -elimination to afford butenolide **34**. Finally, dihydropyran formation was accomplished by removal of the silyl protective group of **34** under acidic conditions, followed by intramolecular Michael addition of the primary hydroxyl group of **35** to afford tricyclic lactone **25**, which is a known key intermediate for dysiherbaine (Scheme 8).

Conclusion

We have explored the stereoselective addition reaction of 2-silyloxyfuran to *N*-gulosyl nitron and have found that the stereoselectivity of the reaction can be controlled by the *N*-chiral auxiliary of the nitron. It was also found that nitrones with a bulkier *C*-substituent afforded greater stereoselectivity. The products **11c**



Scheme 7 Synthesis of lactone **30** via *N*-methylation.



Scheme 8 Synthesis of lactone **25**.

and **11d** of the present reaction were successfully applied to the synthesis of polyoxin C, and adduct **11d** was transformed to a synthetic intermediate of dysiherbaine.

Experimental

General

Melting points were determined with a Yanagimoto micro melting point apparatus and are uncorrected. Optical rotations were measured with a JASCO DIP-140 or Horiba SEPA-300 digital polarimeter. Infrared spectra (IR) were recorded with a Shimadzu FTIR-8100. ^1H NMR spectra were recorded on a JEOL JNM-EX270 (270 MHz), a JEOL JNM-AL300 (300 MHz), a JEOL JNM-GSX400 (400 MHz) or a JEOL JNM-GSX500 (500 MHz) spectrometer. The chemical shifts are expressed in ppm downfield from tetramethylsilane ($\delta = 0$) as an internal standard (CDCl_3 solution). ^{13}C NMR spectra were recorded on a JEOL JNM-EX270 (67.5 MHz), a JEOL JNM-AL300 (75 MHz), a JEOL JNM-GSX400 (100 MHz) or a JEOL JNM-GSX500 (125 MHz) spectrometer. The chemical shifts are reported in ppm, relative to the central line of the triplet at 77.0 ppm for CDCl_3 . Measurements of mass spectra (MS) and high-resolution MS (HRMS) were performed with a JEOL JMS-SX102A or JEOL JMS-DX302 mass spectrometer. Column chromatography was carried out on silica gel (silica gel 40–50 μm neutral, Kanto Chemical Co., Inc.). Merck precoated thin layer chromatography (TLC) plates (silica gel 60 F_{254} , 0.25 mm, Art 5715) were used for the TLC analysis. After extractive workup, organic layers were dried over anhydrous sodium sulfate or anhydrous magnesium sulfate and the solvent was removed by rotary evaporation under reduced pressure.

General procedure for the preparation of adducts **11** from oxime **9** and aldehydes **10**

A mixture of oxime **9** (1.0 equiv.), an aldehyde **10** (1.1 equiv.), and MgSO_4 in CHCl_3 was stirred overnight at room temperature. The mixture was filtered through a pad of Celite[®]. The filtrate was concentrated *in vacuo*, and the residue was passed through a short column of silica gel to afford nitrone **8** as a colorless solid. Nitrone **8** was used for the next step without further purification. To a stirred solution of nitrone **8** (0.1 mmol) in CH_2Cl_2 (3 mL) was added 2-trimethylsilyloxyfuran (**5**) (0.15 mmol) and TMSOTf (0.01 mmol) at -78°C . The mixture was stirred at the same temperature for 15 min, then diluted with a saturated solution of NaHCO_3 , and extracted with CH_2Cl_2 . After drying (MgSO_4), the organic phase was concentrated *in vacuo*. The residue was dissolved in CH_2Cl_2 –THF (1 : 1, 5 mL). TBAF (0.01 mmol) was added at 0°C , and the mixture was stirred for 10 min. Water (2 mL) was added, and the whole was extracted with CH_2Cl_2 . The extract was stirred with MgSO_4 and Florisil[®]. After filtration, the filtrate was concentrated *in vacuo*. The residue was subjected to column chromatography on silica gel to afford adducts **11–14**.

(3*R*,3*aS*,6*aR*)-3-Benzoyloxymethyl-*N*-(2',3':5',6'-*O*-diisopropylidene- α -L-gulofuranosyl)tetrahydrofuro[2,3-*d*]isoxazol-5-one (**11a**)

Following the general procedure, (*Z*)-2-benzyloxy-*N*-(2,3:5,6-*O*-diisopropylidene- α -L-gulofuranosyl)ethylideneamine *N*-oxide (**8a**) (176 mg, 72%) was prepared from oxime **9** (165 mg, 0.60 mmol) and aldehyde **10a** (99.7 mg, 0.66 mmol). It was used for the next step without further purification. **8a**: IR (CHCl_3) 3019, 1221, 1213 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.23 (3H, s), 1.32 (3H, s), 1.38 (3H, s), 1.40 (3H, s), 3.62 (1H, dd, $J = 8.4, 7.2$ Hz), 4.13 (1H, dd, $J = 8.4, 6.6$ Hz), 4.27 (1H, ddd, $J = 8.3, 7.2, 6.6$ Hz),

4.35 (1H, dd, $J = 12.9, 4.4$ Hz), 4.40 (1H, dd, $J = 12.9, 4.4$ Hz), 4.43 (1H, dd, $J = 8.3, 4.4$ Hz), 4.50 (2H, s), 4.74 (1H, dd, $J = 6.0, 4.4$ Hz), 5.12 (1H, d, $J = 6.0$ Hz), 5.31 (1H, s), 7.08 (1H, t, $J = 4.4$ Hz), 7.21–7.32 (5H, m); MS (EI) m/z : 408 ($M^+ + 1$). Following the general procedure, a 76 : 13 : 8 : 3 mixture of bicyclic adducts **11a–14a** (51 mg, 84%) was obtained from nitrone **8a** (50 mg, 0.12 mmol), furan **5** (28 mg, 0.18 mmol), and TMSOTf (2.2 μL , 1.2 μmol). The ratio was estimated by HPLC [JASCO-Fine pack SIL-5, AcOEt–hexane (3 : 2), 1.1 mL min^{-1} , tR: 8.50 (13%), 9.40 (76%), 10.38 (3%), 12.00 (8%)]. The major isomer **11a** was obtained by column chromatography on silica gel with AcOEt–hexane (3 : 2). **11a**: [α]_D¹⁷ +14.1 (c 0.83, CHCl_3); IR (CHCl_3) 1790 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.22 (3H, s), 1.32 (3H, s), 1.35 (3H, s), 1.43 (3H, s), 2.61 (1H, dd, $J = 18.7, 1.1$ Hz), 2.70 (1H, dd, $J = 18.7, 5.3$ Hz), 3.52–3.58 (2H, m), 3.61 (1H, dd, $J = 8.4, 7.0$ Hz), 3.70 (1H, d, $J = 10.1$ Hz), 3.95 (1H, dd, $J = 8.3, 3.9$ Hz), 4.13 (1H, dd, $J = 8.4, 7.8$ Hz), 4.28 (1H, br ddd, $J = 8.3, 7.8, 7.0$ Hz), 4.45 (1H, d, $J = 12.1$ Hz), 3.53 (1H, d, $J = 12.1$ Hz), 4.59 (1H, dd, $J = 6.1, 3.9$ Hz), 4.64 (1H, br ddd, $J = 5.4, 4.4, 1.0$ Hz), 4.67 (1H, s), 4.85 (1H, d, $J = 6.1$ Hz), 5.10 (1H, br d, $J = 4.6$ Hz), 7.23–7.31 (5H, m); ^{13}C NMR (75 MHz, CDCl_3) δ 24.9, 25.3, 26.1, 26.8, 34.5, 65.9, 68.6, 68.9, 73.5, 75.6, 77.0, 80.4, 83.7, 84.7, 89.0, 99.6, 109.7, 113.0, 127.7, 127.9, 128.5, 138.0, 174.5; HRMS (EI) m/z calcd for $\text{C}_{25}\text{H}_{33}\text{NO}_9$ 491.2153, found 491.2148.

(3*R*,3*aS*,6*aR*)-*N*-(2',3':5',6'-*O*-diisopropylidene- α -L-gulofuranosyl)-3-(triisopropylsilyloxymethyl)tetrahydrofuro[2,3-*d*]isoxazol-5-one (**11b**)

Following the general procedure, (*Z*)-*N*-(2,3:5,6-*O*-diisopropylidene- α -L-gulofuranosyl)-2-triisopropylsilyloxyethylideneamine *N*-oxide (**8b**) (139 mg, 63%) was prepared from oxime **9** (129 mg, 0.47 mmol) and aldehyde **10b** (110 mg, 0.52 mmol). This material was unstable, and was therefore used for the next step without further purification. Following the general procedure, a 74 : 21 : 5 mixture of bicyclic adducts (70 mg, 80%) was obtained from nitrone **8b** (74 mg, 0.16 mmol), furan **5** (37 mg, 0.24 mmol), and TMSOTf (2.8 μL , 1.6 μmol). The ratio was estimated by ^1H NMR (300 MHz). The major isomer **11b** was obtained by column chromatography on silica gel with AcOEt–hexane (1 : 2). **11b**: [α]_D¹⁷ +3.3 (c 0.53, CHCl_3); IR (CHCl_3) 1786 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 1.06 (3H, s), 1.07 (18H, s), 1.29 (3H, s), 1.38 (3H, s), 1.41 (3H, s), 1.44 (3H, s), 2.70 (1H, d, $J = 18.5$ Hz), 2.78 (1H, dd, $J = 18.5, 5.4$ Hz), 3.64 (2H, m), 3.66 (1H, dd, $J = 8.3, 6.4$ Hz), 3.99 (1H, dd, $J = 10.0, 8.3$ Hz), 4.00 (1H, dd, $J = 8.3, 3.9$ Hz), 4.19 (1H, dd, $J = 8.3, 6.6$ Hz), 4.33 (1H, br ddd, $J = 8.3, 6.6, 6.4$ Hz), 4.64 (1H, dd, $J = 6.1, 3.9$ Hz), 4.73 (1H, br dd, $J = 5.4, 4.4$ Hz), 4.74 (1H, s), 4.88 (1H, d, $J = 6.1$ Hz), 5.27 (1H, d, $J = 4.4$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 12.0, 18.1, 24.9, 25.5, 26.1, 26.8, 35.3, 62.3, 66.0, 70.1, 75.8, 77.0, 80.5, 83.7, 84.7, 89.1, 99.2, 109.5, 112.8, 173.9; HRMS (EI) m/z calcd for $\text{C}_{27}\text{H}_{47}\text{NO}_9\text{Si}$ 557.3018, found 557.3022.

(3*R*,3*aS*,6*aR*)-3-*tert*-Butyldiphenylsilyloxymethyl-*N*-(2',3':5',6'-*O*-diisopropylidene- α -L-gulofuranosyl)tetrahydrofuro[2,3-*d*]isoxazol-5-one (**11c**)

Following the general procedure, (*Z*)-2-*tert*-butyldiphenylsilyloxy-*N*-(2,3:5,6-*O*-diisopropylidene- α -L-gulofuranosyl)ethylideneamine

N-oxide (**8c**) (283 mg, 93%) was prepared from oxime **9** (151 mg, 0.55 mmol) and aldehyde **10c** (181 mg, 0.61 mmol). It was used for the next step without further purification. IR (CHCl₃) 2994, 1219, 1210 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.04 (9H, s), 1.28 (3H, s), 1.38 (3H, s), 1.43 (3H, s), 1.45 (3H, s), 3.67 (1H, dd, *J* = 8.3, 6.2 Hz), 4.18 (1H, dd, *J* = 8.3, 6.2 Hz), 4.32 (1H, br dt, *J* = 8.8, 6.2 Hz), 4.43 (1H, dd, *J* = 8.8, 3.9 Hz), 4.61 (2H, br d, *J* = 3.9 Hz), 4.72 (1H, dd, *J* = 5.8, 3.9 Hz), 5.10 (1H, d, *J* = 5.8 Hz), 5.32 (1H, s), 7.14 (1H, t, *J* = 3.9 Hz), 7.32–7.43 (6H, m), 7.59–7.65 (4H, m); HRMS (EI) *m/z* calcd for C₃₀H₄₁NO₇Si 555.2650, found 555.2646. Following the general procedure, an 86:8:6 mixture of bicyclic adducts (91 mg, 80%) was obtained from nitron **8c** (100 mg, 0.18 mmol), furan **5** (42 mg, 0.27 mmol), and TMSOTf (3.2 μL, 1.8 μmol). The ratio was estimated by HPLC [JASCO-Fine pack SIL-5, AcOEt–hexane (1:1), 1.0 mL min⁻¹, tR: 9.04 (86%), 9.40 (76%), 17.08 (6%)]. The major isomer **11c** was obtained by column chromatography on silica gel with AcOEt–hexane (3:2). **11c**: mp 166–167 °C (AcOEt–hexane); [α]_D²¹ +10.1 (*c* 0.99, CHCl₃); IR (CHCl₃) 1790 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.00 (9H, s), 1.10 (3H, s), 1.22 (3H, s), 1.24 (3H, s), 1.36 (3H, s), 2.62 (1H, dd, *J* = 18.5, 1.5 Hz), 2.70 (1H, dd, *J* = 18.5, 4.6 Hz), 3.50 (1H, dd, *J* = 8.3, 7.1 Hz), 3.58 (1H, dd, *J* = 9.9, 6.4 Hz), 3.63 (1H, ddd, *J* = 6.4, 3.8, 1.1 Hz), 3.77 (1H, dd, *J* = 8.2, 4.0 Hz), 3.92 (1H, dd, *J* = 9.9, 3.8 Hz), 4.08 (1H, dd, *J* = 8.3, 6.6 Hz), 4.21 (1H, ddd, *J* = 8.2, 7.1, 6.6 Hz), 4.53 (1H, dd, *J* = 6.1, 4.0 Hz), 4.65 (1H, td, *J* = 4.6, 1.5 Hz), 4.67 (1H, s), 4.81 (1H, d, *J* = 6.1 Hz), 5.16 (1H, dd, *J* = 4.6, 1.1 Hz), 7.32–7.45 (6H, m), 7.62–7.66 (4H, m); ¹³C NMR (100 MHz, CDCl₃) δ 19.4, 25.0, 25.5, 26.2, 26.4, 27.0, 35.0, 62.9, 65.9, 69.5, 75.7, 77.2, 80.5, 83.5, 84.5, 89.0, 99.2, 109.5, 112.9, 127.6, 127.7, 129.7, 129.8, 132.6, 132.9, 135.4, 135.5, 173.9; HRMS (EI) *m/z* calcd for C₃₄H₄₅NO₉Si 639.2861, found 639.2868. Anal. Calcd for C₃₄H₄₅NO₉Si: C, 68.83; H, 7.09; N, 2.19. Found: C, 63.55; H, 7.13; N, 2.16.

[3*R*,3*aS*,6*aR*,(4*S*)]-*N*-(2',3':5',6'-*O*-Diisopropylidene- α -L-gulofuranosyl)-3-(2,2-dimethyl-[1,3]dioxolan-4-yl)tetrahydrofuro[2,3-*d*]isoxazol-5-one (11d**)**

(a) Following the general procedure, (4*S*)-(Z)-*N*-(2,3:5,6-*O*-diisopropylidene- α -L-gulofuranosyl)(2,2-dimethyl-[1,3]dioxolan-4-yl)methyleneamine *N*-oxide (**8d**) (175 mg, 63%) was prepared from oxime **9** (200 mg, 0.72 mmol) and aldehyde **10d** (103 mg, 0.79 mmol). It was used for the next step without further purification. **8d**: IR (CHCl₃) 2992, 1221, 1217 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.29 (3H, s), 1.37 (6H, s), 1.41 (3H, s), 1.43 (3H, s), 1.46 (3H, s), 3.69 (1H, dd, *J* = 8.4, 7.2 Hz), 3.69 (1H, dd, *J* = 8.6, 5.7 Hz), 4.18 (1H, dd, *J* = 8.4, 6.6 Hz), 4.31 (1H, br ddd, *J* = 8.4, 7.2, 6.6 Hz), 4.33 (1H, t, *J* = 8.6 Hz), 4.54 (1H, dd, *J* = 8.4, 4.4 Hz), 4.83 (1H, dd, *J* = 5.9, 4.4 Hz), 5.09 (1H, br ddd, *J* = 8.6, 5.7, 5.0 Hz), 5.16 (1H, d, *J* = 5.9 Hz), 5.31 (1H, s), 7.09 (1H, d, *J* = 5.0 Hz); HRMS (EI) *m/z* calcd for C₁₈H₂₉NO₈ 387.1891, found 387.1886. Following the general procedure, bicyclic adduct **11d** (55.7 mg, 72%) was obtained as a sole product from nitron **8d** (60 mg, 0.15 mmol), furan **5** (36 mg, 0.23 mmol), and TMSOTf (2.8 μL, 1.5 μmol). **11d**: mp 172–173 °C (benzene–hexane); [α]_D²¹ +23.7 (*c* 0.90, CHCl₃); IR (CHCl₃) 1792 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.26 (3H, s), 1.32 (3H, s), 1.36 (3H, s), 1.39 (3H, s), 1.42 (3H, s), 1.44 (3H, s), 2.71 (1H, dd, *J* = 18.8, 1.0 Hz), 2.79 (1H, dd, *J* =

18.8, 5.6 Hz), 3.56 (1H, dd, *J* = 4.6, 1.3 Hz), 3.68 (1H, dd, *J* = 8.5, 6.7 Hz), 3.79 (1 H, dd, *J* = 8.8, 5.9 Hz), 4.03 (1 H, dd, *J* = 8.3, 3.4 Hz), 4.16 (1H, dd, *J* = 8.8, 5.9 Hz), 4.19 (1 H, dd, *J* = 8.5, 6.7 Hz), 4.29 (1H, ddd, *J* = 6.8, 5.9, 4.6 Hz), 4.34 (1H, dt, *J* = 8.3, 6.7 Hz), 4.65 (1H, s), 4.65 (1H, dd, *J* = 6.1 3.4 Hz), 4.73 (1H, ddd, *J* = 5.6, 4.6, 1.0 Hz), 4.90 (1H, d, *J* = 6.1 Hz), 5.27 (1H, dd, *J* = 4.6, 1.3 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 24.7, 25.1, 25.4, 26.2, 26.5, 26.9, 35.1, 66.0, 67.5, 71.9, 73.9, 75.5, 77.5, 80.4, 84.1, 84.7, 87.9, 100.1, 109.7, 109.9, 113.1, 173.6; HRMS (EI) *m/z* calcd for C₂₂H₃₃NO₁₀ 471.2102, found 471.2101. Anal. Calcd for C₂₂H₃₃NO₁₀: C, 56.04; H, 7.05; N, 2.97. Found: C, 55.72; H, 6.95, N, 2.93.

(b) Following the general procedure, **11d** (1.19 g, 87%) was obtained as a sole product from nitron **8d** (1.19 g, 3.06 mmol), furan **5** (717 mg, 4.59 mmol), and TMSOTf (68 mg, 0.306 mmol).

(3*R*,3*aS*,6*aR*)-3-(*tert*-Butyldiphenylsilyloxymethyl)-*N*-(*tert*-butyloxycarbonyl)tetrahydrofuro[2,3-*d*]isoxazol-5-one (19**)**

To a stirred solution of bicyclic adduct **11c** (500 mg, 0.78 mmol) in CH₃CN (10 mL) was added a 0.96 M solution of HClO₄ (1.6 mL, 1.5 mmol). The mixture was stirred at room temperature for 5 h and neutralized with powdered NaHCO₃. Then Boc₂O (853 mg, 3.9 mmol) was added, and the mixture was stirred overnight, diluted with water, and extracted with CH₂Cl₂. The organic solution was washed with brine, and dried over MgSO₄. After filtration, the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel with AcOEt–hexane (1:1) to afford **19** (246 mg, 64%) as a colorless oil. [α]_D²¹ –18.8 (*c* 1.32, CHCl₃); IR (CHCl₃) 1794, 1734, 1429, 1371 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.01 (9H, s), 1.37 (9H, s), 2.68 (1H, dd, *J* = 19.2, 7.1 Hz), 2.91 (1H, d, *J* = 19.2 Hz), 3.56 (1H, dd, *J* = 10.6, 7.7 Hz), 3.82 (1H, dd, *J* = 10.6, 5.3 Hz), 4.46 (1H, dd, *J* = 7.7, 5.3 Hz), 4.72 (1H, br dd, *J* = 7.1, 5.3 Hz), 5.28 (1H, d, *J* = 5.3 Hz), 7.29–7.41 (6H, m), 7.56–7.60 (4H, m); ¹³C NMR (100 MHz, CDCl₃) δ 19.4, 27.1, 28.2, 35.2, 62.1, 67.6, 79.7, 83.9, 86.9, 128.4, 130.5, 130.6, 133.1, 133.2, 136.0, 136.1, 158.0, 173.9; MS (EI) *m/z* 453 (M+CO₂), 424, 384, 340, 319. HRMS (EI) *m/z* calcd for C₂₆H₃₅NO₄Si–CO₂ 453.2333, found 453.2335.

[3*R*,3*aS*,6*aR*,(2*S*)]-*N*-(*tert*-Butyloxycarbonyl)-3-(1,2-dihydroxyethyl)tetrahydrofuro[2,3-*d*]isoxazol-5-one (20**)**

To a stirred solution of bicyclic adduct **11d** (258 mg, 0.583 mmol) in CH₃CN (10 mL) was added a 1 M solution of HClO₄ (1.17 mL, 1.17 mmol). The mixture was stirred at room temperature for 15 min and neutralized with powdered NaHCO₃. Then Boc₂O (636 mg, 2.91 mmol) was added, and the mixture was stirred overnight, dried over MgSO₄, and filtered. The filtrate was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel with AcOEt–CH₂Cl₂ (5:1) to afford **20** (144 mg, 86%) as a colorless oil. [α]_D²¹ –16.1 (*c* 1.80, CHCl₃); IR (CHCl₃) 3600, 1794, 1736, 1371 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 1.49 (9H, s), 2.84 (1H, br s), 2.85 (1H, dd, *J* = 18.5, 6.9 Hz), 3.00 (1H, d, *J* = 18.5 Hz), 3.29 (1H, d, *J* = 7.3 Hz), 3.61 (1H, ddt, *J* = 9.2, 7.3, 4.0 Hz), 3.77 (1H, dd, *J* = 15.5, 4.0 Hz), 3.85 (1H, dd, *J* = 15.5, 4.0 Hz), 4.45 (1H, d, *J* = 9.2 Hz), 5.03 (1H, br dd, *J* = 6.9, 5.3 Hz), 5.59 (1H, d, *J* = 5.3 Hz); ¹³C NMR (67.8 MHz,

CDCl₃) δ 28.0, 35.0, 63.2, 67.5, 69.1, 79.9, 84.3, 86.7, 157.9, 173.9; MS (EI) m/z 230 (M⁺-*tert*-Bu), 216, 189, 128, 110, 57.

(3*R*,3*aS*,6*aR*)-3-(Hydroxymethyl)-*N*-(*tert*-butyloxycarbonyl)-tetrahydrofuro[2,3-*d*]isoxazol-5-one (21)

(a) Preparation of **21** from **19**. A 1.0 M solution of TBAF (38 μ L, 38 μ mol) was adjusted to pH 4–5 by adding 80% AcOH. To the mixture was added a solution of **19** (18.7 mg, 37.7 μ mol) in THF (2 mL) at 0 °C. The mixture was stirred at room temperature for 3 h, diluted with water, and extracted with AcOEt. The organic phase was dried over MgSO₄, and filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel with AcOEt–hexane (2 : 1) to give **21** (9.6 mg, 98%) as a colorless oil. $[\alpha]_D^{21}$ –23.1 (*c* 0.96, CHCl₃); IR (CHCl₃) 1794, 1736, 1371 cm⁻¹; ¹H-NMR (300 MHz, CDCl₃) δ 1.49 (9H, s), 2.12 (1H, br s), 2.81 (1H, dd, *J* = 19.2, 7.1 Hz), 3.03 (1H, dd, *J* = 19.2, 0.5 Hz), 3.78 (2H, m), 4.56 (1H, t, *J* = 5.7 Hz), 4.98 (1H, ddd, *J* = 7.1, 5.3, 0.5 Hz), 5.28 (1H, d, *J* = 5.3 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 28.1, 34.9, 61.2, 67.9, 79.8, 84.0, 86.6, 157.5, 173.3; HRMS (EI) m/z calcd for C₁₁H₁₇NO₆ 259.1055, found 259.1064.

(b) Preparation of **21** from **20**. A mixture of diol **20** (31.8 mg, 0.11 mmol) and NaIO₄ (35.3 mg, 0.16 mmol) in MeOH–H₂O (10 : 1, 2 mL) was stirred at 0 °C for 1 h. After evaporation, the residue was partitioned between water and CH₂Cl₂. The aqueous phase was further extracted with CH₂Cl₂. The combined organic phase was washed with brine, dried over MgSO₄, and filtered, and the filtrate was concentrated *in vacuo*. The residue was dissolved in Et₂O (2 mL). To this solution was added a 0.1 M solution of Zn(BH₄)₂ in Et₂O (3.3 mL, 0.33 mmol) at 0 °C. After 1 h, 1 N HCl (1 mL) was added, and the mixture was extracted with AcOEt. The AcOEt solution was washed successively with a saturated solution of NaHCO₃ and brine, and dried over MgSO₄. After filtration, the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel with CH₂Cl₂–MeOH (10 : 1) to give **21** (16.0 mg, 56%) as a colorless oil. $[\alpha]_D^{21}$ –22.1 (*c* 0.81, CHCl₃). Spectral data of this sample were identical with those obtained in (a).

(4*S*)-4-[(2*R*,3*R*)-3-Hydroxy-5-oxo-tetrahydro-furan-2-yl]-2,2-dimethyloxazolidine-3-carboxylic acid *tert*-butyl ester (22)

A solution of **21** (142 mg, 0.55 mmol) and Mo(CO)₆ (289 mg, 1.1 mmol) in CH₃CN–H₂O (10 : 1, 15 mL) was heated at reflux for 1.5 h. The mixture was filtered through a pad of Celite[®], and the filtrate was concentrated *in vacuo*. The residue was passed through a pad of silica gel, and the filtrate was concentrated *in vacuo*. The residue was dissolved in toluene (10 mL) containing 2,2-dimethoxypropane (338 mL, 2.75 mmol) and PPTS (13.8 mg, 55 μ mol), and the solution was heated at reflux for 1.5 h. The mixture was concentrated *in vacuo*, and the residue was purified by column chromatography on silica gel with AcOEt–hexane (2 : 3) to give **22** (89.5 mg, 54%). $[\alpha]_D^{23}$ +76.2 (*c* 0.79, CHCl₃); IR (CHCl₃) 3300, 1800, 1779, 1671, 1402 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 1.51 (9H, s), 1.54 (3H, s), 1.57 (3H, s), 2.61 (1H, d, *J* = 17.3 Hz), 2.72 (1H, ddd, *J* = 17.3, 4.6, 2.0 Hz), 4.04 (1H, dd, *J* = 9.5, 5.1 Hz), 4.14 (1H, dd, *J* = 10.2, 2.0 Hz), 4.24 (1H, d, *J* = 9.5 Hz), 4.30 (1H, dd, *J* = 10.2, 5.1 Hz), 4.34 (1H, dt, *J* = 4.6, 2.0 Hz), 5.71 (1H,

br t, *J* = 2.0 Hz); ¹³C NMR (67.8 MHz, CDCl₃) δ 24.2, 27.9, 28.4, 38.8, 54.5, 65.4, 67.3, 82.5, 82.9, 94.4, 154.1, 174.6; HRMS (EI) m/z Calcd for C₁₃H₂₀NO₆–CH₃ 286.1289, found 286.1287.

(4*R*)-4-[(2*S*)-3,4-Dihydro-5-oxo-furan-2-yl]-2,2-dimethyloxazolidine-3-carboxylic acid *tert*-butyl ester (23)

To a stirred solution of **22** (12.9 mg, 42.8 μ mol) in CH₂Cl₂ (1 mL) were added MsCl (13 μ L, 171 μ mol) and Et₃N (47 μ L, 342 μ mol) at room temperature. The mixture was stirred for 2 h, diluted with water, and extracted with Et₂O. The Et₂O solution was washed with brine, and dried over MgSO₄. After filtration, the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel with AcOEt–hexane (1 : 1) to give **23** (11.6 mg, 96%) as an oil. This compound was used without further purification. IR (CHCl₃) 3028, 1794, 1761, 1698, 1686 cm⁻¹; ¹H NMR (270 MHz, C₆D₆, 60 °C) δ 1.32 (9H, s), 1.37 (3H, s), 1.53 (3H, s), 3.42 (1H, dd, *J* = 9.2, 5.3 Hz), 3.53 (1H, br s), 3.70 (1H, d, *J* = 9.2 Hz), 4.60 (1H, br s), 5.60 (1H, dd, *J* = 5.7, 2.0 Hz), 6.81 (1H, dd, *J* = 5.7, 1.3 Hz).

(4*R*)-4-[(2*R*,3*R*,4*R*)-3,4-Dihydroxy-5-oxo-tetrahydrofuran-2-yl]-2,2-dimethyloxazolidine-3-carboxylic acid *tert*-butyl ester (18)

Following Garner's procedure, this material was obtained from **23** and Me₃NO, and OsO₄. $[\alpha]_D^{21}$ +31.0 (*c* 0.85, CHCl₃), *lit.*^{12g} $[\alpha]_D$ +31.8 (*c* 0.87, CHCl₃); IR (CHCl₃) 2984, 1786, 1695, 1678 cm⁻¹; ¹H NMR (400 MHz, C₆D₆, 60 °C) δ 1.31 (9H, s), 1.33 (3H, s), 1.48 (3H, s), 2.49 (2H, br s), 3.41 (1H, dd, *J* = 9.4, 5.3 Hz), 3.48 (1H, dd, *J* = 9.4, 5.3 Hz), 3.68 (1H, d, *J* = 9.4 Hz), 4.30 (1H, d, *J* = 9.4 Hz), 4.39 (1H, br s); ¹³C NMR (100 MHz, C₆D₆, 60 °C) δ 24.2, 27.9, 28.4, 57.9, 65.6, 69.2, 69.7, 81.1, 84.6, 94.8, 153.2, 174.1; HRMS (EI) m/z calcd for C₁₃H₂₀NO₇–CH₃ 302.1238, found 302.1239.

(3*R*,3*aS*,6*aR*)-3-[(*S*)-(2-*tert*-Butyldiphenylsilyloxy-1-hydroxyethyl)]-2-(*tert*-butyloxycarbonyl)tetrahydrofuro[2,3-*d*]isoxazol-5-one (26)

To a stirred solution of diol **20** (2.23 g, 7.76 mmol) in DMF were added imidazole (1.59 g, 23.3 mmol) and TBDPSCI (2.77 g, 10.1 mmol) at room temperature, and stirring was continued for 30 min. The mixture was partitioned between water and Et₂O, and the organic layer was successively washed with water and brine, dried (MgSO₄), and concentrated under reduced pressure. The residue was chromatographed on silica gel (hexane–EtOAc, 2 : 1) to give **26** (3.40 g, 83%) as a colorless oil. $[\alpha]_D^{23}$ –20.6 (*c* 0.30, CHCl₃); IR (CHCl₃) 1792, 1734 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 1.09 (9H, s), 1.45 (9H, s), 2.69 (1H, d, *J* = 6.6 Hz), 2.79 (1H, dd, *J* = 19.3, 7.3 Hz), 3.05 (1H, d, *J* = 19.3 Hz), 3.58 (1H, m), 3.78 (1H, dd, *J* = 10.6, 4.3 Hz), 3.86 (1H, dd, *J* = 10.6, 4.6 Hz), 4.58 (1H, d, *J* = 8.5 Hz), 4.97 (1H, dd, *J* = 7.3, 5.2 Hz), 5.57 (1H, d, *J* = 5.2 Hz), 7.35–7.49 (6H, m, Ph), 7.64–7.69 (4H, m, Ph); ¹³C NMR (67.5 MHz, CDCl₃) δ 19.2, 26.9, 28.0, 35.0, 63.9, 67.7, 68.9, 79.8, 83.9, 86.5, 127.9, 130.0, 132.5, 135.5, 157.8, 173.9; MS (EI) m/z 484 (2.5, -*t*-Bu), 370, 292. *Anal.* Calcd for C₂₈H₃₇NO₇Si: C, 63.73; H, 7.07; N, 2.65. Found: C, 63.56; H, 7.21; N, 2.63.

(3*R*,3*aS*,6*aR*)-3-[(*S*)-2-*tert*-Butyldiphenylsilyloxy-1-hydroxyethyl]-tetrahydrofuro[2,3-*d*]isoxazol-5-one (27)

To a stirred solution of **24** (1.45 g, 2.75 mmol) in CH₂Cl₂ (75 ml) was added anhydrous TsOH (1.14 g, 6.60 mmol) at 0 °C, and stirring was continued at room temperature for 7 h. The mixture was poured into a saturated aqueous solution of NaHCO₃, and the whole was extracted with CHCl₃, dried (MgSO₄), and concentrated under reduced pressure. The residue was chromatographed on silica gel (hexane–EtOAc, 1.7 : 1) to give **25** (1.05 g, 90%) as a colorless oil. [α]_D²⁰ +49.4 (*c* 0.22, CHCl₃); IR (CHCl₃) 1786 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 1.08 (9H, s, *t*-Bu), 2.64 (1H, d, *J* = 5.3 Hz), 2.68 (1H, dd, *J* = 19.1, 1.3 Hz), 2.84 (1H, dd, *J* = 19.1, 6.7 Hz), 3.53 (1H, m), 3.71 (1H, br), 3.84 (2H, d, *J* = 4.6 Hz), 4.77 (1H, ddd, *J* = 6.7, 6.3, 1.3 Hz), 5.51 (1H, br), 5.83 (1H, dd, *J* = 6.3, 0.9 Hz), 7.37–7.48 (6H, m), 7.63–7.66 (4H, m); ¹³C NMR (67.5 MHz, CDCl₃) δ 19.3, 26.9, 34.6, 64.9, 67.9, 68.3, 87.8, 127.9, 130.1, 132.6, 135.5, 173.9. MS (EI) *m/z* 370, 293, 292. *Anal.* Calcd for C₂₅H₂₉NO₅Si: C, 64.61; H, 6.84; N, 3.28. Found: C, 64.33; H, 7.00; N, 3.30.

(3*R*,3*aS*,6*aR*)-3-[(*S*)-2-*tert*-Butyldiphenylsilyloxy-2-hydroxyethyl]-2-methyl-tetrahydrofuro[2,3-*d*]isoxazole-5-one (30)

To a stirred solution of **27** (1.00 g, 2.35 mmol) in EtOH (5 mL) was added a 35% aqueous solution of HCHO (1.66 mL, 20 mmol) at room temperature, and the mixture was heated at 75 °C for 6 h. After concentration, the residue was dissolved in CH₃CN (50 mL). Trifluoroacetic acid (1.78 mL, 23.5 mmol) and Et₃SiH (2.81 mL, 17.6 mmol) were added at room temperature, and then the mixture was heated at 60 °C for 1.5 h and poured into a saturated aqueous solution of NaHCO₃. The whole was extracted with CHCl₃. The organic extract was dried (MgSO₄) and concentrated under reduced pressure. The residue was chromatographed on silica gel with (hexane–EtOAc, 1.5 : 1) to give **30** (880 mg, 85%) as colorless oil. [α]_D²⁴ –0.3 (*c* 0.48, CHCl₃); IR (CHCl₃) 1786 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1.08 (9H, s), 2.64 (1H, d, *J* = 19.2 Hz), 2.72 (3H, s), 2.73 (1H, dd, *J* = 19.2, 5.5 Hz), 2.95 (1H, dd, *J* = 4.0, 2.4 Hz), 3.78 (1H, m), 3.78 (2H, d, *J* = 4.9 Hz), 4.58 (1H, dd, *J* = 5.5, 4.9 Hz), 5.31 (1H, dd, *J* = 4.9, 2.4 Hz), 7.37–7.48 (6H, m, Ph), 7.63–7.66 (4H, m, Ph); ¹³C NMR (67.5 MHz, CDCl₃) δ 19.2, 26.8, 34.2, 44.1, 64.9, 69.0, 75.8, 87.6, 127.9, 130.0, 132.7, 135.5, 174.6. MS (EI) *m/z* 441, 384, 307. *Anal.* Calcd for C₂₈H₃₅NO₇Si: C, 65.28; H, 7.08; N, 3.17. Found: C, 65.02; H, 7.47; N, 3.09.

(3*R*,3*aS*,6*aR*)-3-[(*S*)-2-*tert*-Butyldiphenylsilyloxyethyl-1-phenyl-carbonyloxy]-2-methyl-tetrahydrofuro[2,3-*d*]isoxazole-5-one (31)

To a stirred solution of **30** (632 mg, 1.43 mmol) and DMAP (350 mg, 2.86 mmol) in CH₃CN (120 mL) was added phenyl chloroformate (336 mg, 2.15 mmol) at 60 °C. After 2 h, further phenyl chloroformate (224 mg, 1.43 mmol) and DMAP (175 mg, 1.43 mmol) were added, and stirring was continued for 2 h at 60 °C. The mixture was poured into a saturated aqueous solution of NaHCO₃, and the whole was extracted with AcOEt. The organic layer was dried (MgSO₄) and concentrated under reduced pressure. The residue was chromatographed on silica gel with (hexane–AcOEt, 3 : 1) to give **31** (698 mg, 89%) as a colorless oil and starting **30** (44.8 mg, 7%). **31**: [α]_D²⁴ +4.7 (*c* 0.38, CHCl₃); IR (CHCl₃) 1786, 1767 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 1.08 (9H, s), 2.65 (1H,

dd, *J* = 18.8, 1.3 Hz), 2.72 (3H, s), 2.75 (1H, dd, *J* = 18.8, 5.3 Hz), 3.02 (1H, dd, *J* = 3.0, 2.6 Hz), 3.93 (1H, dd, *J* = 11.5, 5.5 Hz), 3.94 (1H, dd, *J* = 11.5, 6.2 Hz), 4.62 (1H, ddd, *J* = 5.3, 4.6, 1.3 Hz), 5.00 (1H, ddd, *J* = 6.2, 5.5, 2.6 Hz), 5.29 (1H, dd, *J* = 4.6, 3.0 Hz), 7.12–7.48 (11H, Ph), 7.68–7.73 (4H, Ph); ¹³C NMR (67.5 MHz, CDCl₃) δ 19.2, 26.7, 33.8, 43.7, 63.1, 74.7, 76.2, 87.4, 126.2, 127.9, 129.5, 129.7, 130.0, 132.5, 135.6, 151.0, 153.0, 174.4. *Anal.* Calcd for C₂₈H₃₅NO₇Si: C, 66.29; H, 6.28; N, 2.49. Found: C, 66.18; H, 6.49; N, 2.42.

(4*R*,5*S*)-5-(*tert*-Butyldiphenylsilyloxymethyl)-3-methyl-4-[(2*R*,3*R*)-tetrahydro-3-hydroxy-5-oxofuran-2-yl]oxazolidine-2-one (33)

A mixture of **31** (38.6 mg, 0.071 mmol) and 20% Pd(OH)₂/C (38.6 mg) in MeOH–H₂O (20 : 1, 1 mL) was stirred for 10 h under an atmosphere of hydrogen. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was chromatographed on silica gel with (hexane–EtOAc, 1 : 1.5) to give **33** (30.1 mg, 91%) as a colorless oil. [α]_D¹⁸ +51.0 (*c* 0.48, CHCl₃); IR (CHCl₃) 1790, 1747 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1.04 (9H, s), 2.53 (1H, d, *J* = 17.4 Hz), 2.60 (1H, dd, *J* = 17.4, 4.6 Hz), 2.99 (3H, s), 3.45 (1H, br), 4.05 (1H, dd, *J* = 11.9, 2.7 Hz), 4.08 (1H, dd, *J* = 11.9, 2.7 Hz), 4.33 (1H, dt, *J* = 8.2, 2.7 Hz), 4.57 (1H, dd, *J* = 8.2, 3.6 Hz), 4.58 (1H, dt, *J* = 9.1, 4.6 Hz), 4.71 (1H, dd, *J* = 9.1, 3.6 Hz), 7.36–7.44 (6H, m), 7.63–7.65 (4H, m); ¹³C NMR (125 MHz, CDCl₃) δ 19.1, 22.6, 26.7, 31.2, 31.6, 39.5, 56.4, 62.4, 68.3, 75.9, 80.8, 127.9, 130.1, 132.2, 132.8, 135.4, 135.6, 135.8, 159.1, 173.8. *Anal.* Calcd for C₂₅H₃₁NO₆Si: C, 63.94; H, 6.65; N, 2.98. Found: C, 64.01; H, 6.98; N, 2.97.

Hatakeyama's lactone 25

Pyridine (30.8 μ L, 0.383 mmol) and chloromethanesulfonyl chloride (17.1 μ L, 0.192 mmol) were added to a stirred solution of **33** (30.0 mg, 0.064 mmol) in CH₂Cl₂ (0.4 mL) at 0 °C, and stirring was continued at room temperature for 5 h. The reaction was quenched by adding water, and the whole was extracted with CHCl₃. The organic layer was successively washed with 1 N HCl and a saturated aqueous solution of NaHCO₃, then dried (MgSO₄), and concentrated under reduced pressure to give crude **34**. The crude **34** was dissolved in CH₃CN. A 47% aqueous solution of HF (0.5 mL) was added, and the mixture was heated at 60 °C for 30 h, adjusted to pH 8 by adding NaHCO₃, further stirred at room temperature for 3 h, and then partitioned between water and CHCl₃. The organic layer was dried (MgSO₄) and concentrated under reduced pressure. The residue was chromatographed on silica gel with (EtOAc–MeOH, 20 : 1) to give **25** (9.6 mg, 71%) as colorless crystals. mp 191–192 °C (EtOAc); *lit*^{15c} 199–201 °C (EtOAc); *lit*^{16d} 192–193 °C (EtOAc); [α]_D²⁴ +128.2 (*c* 0.200, CH₃OH); *lit*^{16d} +131.8 (*c* 0.35, CH₃OH); ¹H NMR (270 MHz, CD₃OD) δ 2.53 (1H, d, *J* = 17.2 Hz), 2.89 (1H, dd, *J* = 17.2, 4.3 Hz), 2.90 (3H, s), 3.76 (1H, dd, *J* = 14.2, 2.0 Hz), 4.16 (1H, dd, *J* = 14.2, 1.3 Hz), 4.16 (1H, dd, *J* = 6.9, 5.9 Hz), 4.30 (1H, dd, *J* = 4.3, 2.3 Hz), 4.44 (1H, ddd, *J* = 6.9, 2.0, 1.3 Hz), 4.72 (1H, dd, *J* = 5.9, 2.3 Hz). These physical data are identical with the reported values.^{15c,16d}

Notes and references

- 1 For reviews on vinylogous Mannich reaction, see: (a) S. K. Bur and S. F. Martin, *Tetrahedron*, 2001, **57**, 3221; (b) G. Casiraghi, F. Zanardi, L. Battistini and G. Rassu, *Synlett*, 2009, 1525; (c) L. Battistini, F. Zanardi, C. Curti and G. Casiraghi, *Chemtracts-Organic Chemistry*, 2010, **23**, 141. For leading references, see: (d) T. Liu, H. Cui, J. Long, B. Li, Y. Wu, L. Ding and Y. Chen, *J. Am. Chem. Soc.*, 2007, **129**, 1878; (e) B. Niess and K. A. Joergensen, *Chem. Commun.*, 2007, 1620; (f) R. Villano, M. R. Acocella, A. Massa, L. Palombi and A. Scettri, *Tetrahedron*, 2007, **63**, 12317; (g) M. Sickert and C. Schneider, *Angew. Chem., Int. Ed.*, 2008, **47**, 3631; (h) A. Yamaguchi, S. Matsunaga and M. Shibasaki, *Org. Lett.*, 2008, **10**, 2319; (i) D. S. Giera, M. Sickert and C. Schneider, *Org. Lett.*, 2008, **10**, 4259.
- 2 For vinylogous Mannich reactions in natural product syntheses, see: (a) A. Deiters, K. Chen, C. T. Eary and S. F. Martin, *J. Am. Chem. Soc.*, 2003, **125**, 4541; (b) D. M. Barnes, L. Bhagavatula, J. DeMattei, A. Gupta, D. R. Hill, S. Manna, M. A. McLaughlin, P. Nichols, R. Premchandran, M. W. Rasmussen, Z. Tian and S. J. Wittenberger, *Tetrahedron: Asymmetry*, 2003, **14**, 3541; (c) T. Nagata, M. Nakagawa and A. Nishida, *J. Am. Chem. Soc.*, 2003, **125**, 7484; (d) R. Alibes, P. Bayon, P. De March, M. Figueredo, J. Font, E. Garcia-Garcia and D. Gonzalez-Galvez, *Org. Lett.*, 2005, **7**, 5107; (e) K. Tokumaru, S. Arai and A. Nishida, *Org. Lett.*, 2006, **8**, 27; (f) G. G. Bardaji, M. Canto, R. Alibes, P. Bayon, F. Busque, P. de March, M. Figueredo and J. Font, *J. Org. Chem.*, 2008, **73**, 7657; (g) D. Gonzalez-Gálvez, E. García-García, R. Alibés, P. Bayón, P. de March, M. Figueredo and J. Font, *J. Org. Chem.*, 2009, **74**, 6199.
- 3 (a) M. V. Spanedda, M. Ourévitche, B. Crousse, J. Bégue and D. Bonnet-Delpon, *Tetrahedron Lett.*, 2004, **45**, 5023; (b) L. D. Bari, S. Guilleme, S. Hermitage, J. A. K. Howard, D. A. Jay, G. Pescitelli, A. Whiting and D. S. Yufit, *Synlett*, 2004, 708; (c) J. M. Aurrecoechea and R. Suero, *Tetrahedron Lett.*, 2005, **46**, 4945; (d) J. M. Aurrecoechea, R. Suero and E. de Torres, *J. Org. Chem.*, 2006, **71**, 8767; (e) K. E. Hardinga and J. M. Southard, *Tetrahedron: Asymmetry*, 2005, **16**, 1845; (f) V. Liautard, V. Desvergnès, K. Itoh, H. Liu and O. R. Martin, *J. Org. Chem.*, 2008, **73**, 3103; (g) J. Yu, Z. Miao and R. Chen, *Org. Biomol. Chem.*, 2011, **9**, 1756.
- 4 (a) E. L. Carswell, M. L. Snapper and A. H. Hoveyda, *Angew. Chem., Int. Ed.*, 2006, **45**, 7230; (b) H. Mandai, K. Mandai, M. L. Snapper and A. H. Hoveyda, *J. Am. Chem. Soc.*, 2008, **130**, 17961; (c) L. C. Wieland, E. M. Vieira, M. L. Snapper and A. H. Hoveyda, *J. Am. Chem. Soc.*, 2009, **131**, 570; (d) Z.-L. Yuan, J.-J. Jiang and M. Shi, *Tetrahedron*, 2009, **65**, 6001; (e) Q.-Y. Zhao, Z.-L. Yuan and M. Shi, *Tetrahedron: Asymmetry*, 2010, **21**, 943; (f) Q. Zhao, Z. Yuan and M. Shi, *Adv. Synth. Catal.*, 2011, **353**, 637; (g) C. Curti, L. Battistini, B. Ranieri, G. Pelosi, G. Rassu, G. Casiraghi and F. Zanardi, *J. Org. Chem.*, 2011, **76**, 2248; (h) T. Akiyama, Y. Honma, J. Itoh and K. Fuchibe, *Adv. Synth. Catal.*, 2008, **350**, 399.
- 5 For general reviews on nucleophilic additions to nitrones, see: (a) M. Lombardo and C. Trombini, *Synthesis*, 2000, 759; (b) M. Lombardo and C. Trombini, *Curr. Org. Chem.*, 2002, **6**, 695; (c) Y. Ukaji and K. Inomata, *Synlett*, 2003, 1075; (d) P. Merino, *Targets in Heterocyclic Systems*, 2003, **7**, 140; (e) P. Merino, *C. R. Chim.*, 2005, **8**, 775; (f) Y. Ukaji and K. Inomata, *Chem. Rec.*, 2010, **10**, 173.
- 6 For references on nucleophilic addition of 2-silyloxyfurans to nitrones, see: (a) C. Camiletti, L. Poletti and C. Trombini, *J. Org. Chem.*, 1994, **59**, 6843; (b) C. Castellari, M. Lombardo, G. Pietropaolo and C. Trombini, *Tetrahedron: Asymmetry*, 1996, **7**, 1059; (c) F. Degiorgis, M. Lombardo and C. Trombini, *Tetrahedron*, 1997, **53**, 11721; (d) F. Degiorgis, M. Lombardo and C. Trombini, *Synthesis*, 1997, 1243; (e) M. Lombardo and C. Trombini, *Tetrahedron*, 2000, **56**, 323.
- 7 N. Mita, O. Tamura, H. Ishibashi and M. Sakamoto, *Org. Lett.*, 2002, **4**, 1111.
- 8 (a) A. Vasella and R. Voeffray, *Helv. Chim. Acta*, 1982, **65**, 1953; (b) A. Vasella, R. Voeffray, J. Pless and Huguenin, *Helv. Chim. Acta*, 1983, **66**, 1241; (c) R. Huber and A. Vasella, *Helv. Chim. Acta*, 1987, **70**, 1461; (d) A. Basha, R. Henry, M. A. McLaughlin, J. D. Ratajczyk and S. J. Wittenberger, *J. Org. Chem.*, 1994, **59**, 6103; (e) A. Abiko, *Chem. Lett.*, 1995, 357; (f) J. R. Flisak, I. Lantos, L. Liu, R. T. Matsuoka, W. L. Mendelson, L. M. Tucker, A. J. Villani and W. Zhang, *Tetrahedron Lett.*, 1996, **37**, 4639; (g) I. Lantos, J. Flisak, L. Liu, R. Matsuoka, W. Mendelson, D. Stevenson, K. Tubman, L. Tucker, W. Zhang, J. Adams, M. Sorenson, R. Garigipati, K. Erhardt and S. Ross, *J. Org. Chem.*, 1997, **62**, 5385; (h) R. Fassler, D. E. Frantz, J. Oetiker and E. M. Carreira, *Angew. Chem., Int. Ed.*, 2002, **41**, 3054; (i) S. K. Patel, S. Py, S. U. Pandya, P. Y. Chavant and Y. Vallee, *Tetrahedron: Asymmetry*, 2003, **14**, 525; (j) D. Topic, P. Aschwanden, R. Faessler and E. M. Carreira, *Org. Lett.*, 2005, **7**, 5329; (k) U. Chiacchio, M. G. Saita, L. Crispino, G. Gumina, S. Mangiafico, V. Pistara, G. Romeo, A. Piperno and E. De Clercq, *Tetrahedron*, 2006, **62**, 1171; *Tetrahedron*, 2007, **63**, 4190.
- 9 (a) H. Iida, K. Kasahara and C. Kibayashi, *J. Am. Chem. Soc.*, 1986, **108**, 4647; (b) K. Kasahara, H. Iida and C. Kibayashi, *J. Org. Chem.*, 1989, **54**, 2225; (c) A. Basha, R. Henry, M. A. McLaughlin, J. D. Ratajczyk and S. J. Wittenberger, *J. Org. Chem.*, 1994, **59**, 6103.
- 10 (a) O. Tamura, N. Mita, N. Kusaka, H. Suzuki and M. Sakamoto, *Tetrahedron Lett.*, 1997, **38**, 429; (b) O. Tamura, N. Iyama and H. Ishibashi, *J. Org. Chem.*, 2004, **69**, 1475; (c) O. Tamura, A. Kanoh, M. Yamashita and H. Ishibashi, *Tetrahedron*, 2004, **60**, 9997; (d) T. Shibue, T. Hirai, I. Okamoto, N. Morita and O. Tamura, *Tetrahedron Lett.*, 2009, **50**, 3845; (e) T. Shibue, T. Hirai, I. Okamoto, N. Morita, H. Masu, I. Azumaya and O. Tamura, *Chem.-Eur. J.*, 2010, **16**, 11678.
- 11 For a review, see: H. Akita, *Heterocycles*, 2009, **77**, 67.
- 12 For synthesis of polyoxin Cs, see: (a) T. Naka, T. Hashizume and M. Nishimura, *Tetrahedron Lett.*, 1971, **12**, 95; (b) N. P. Damodaran, G. H. Jones and J. G. Moffatt, *J. Am. Chem. Soc.*, 1971, **93**, 3812; (c) H. Ohrui, H. Kuzuhara and S. Emoto, *Tetrahedron Lett.*, 1971, **12**, 4267; (d) F. Tabusa, T. Yamada, K. Suzuki and K. Mukaiyama, *Chem. Lett.*, 1984, 405; (e) T. Mukaiyama, K. Suzuki, T. Yamada and Tabusa, *Tetrahedron*, 1990, **46**, 265; (f) P. Garner and J. M. Park, *Tetrahedron Lett.*, 1989, **30**, 5065; (g) P. Garner and J. M. Park, *J. Org. Chem.*, 1990, **55**, 3772; (h) A. G. M. Barrett and S. A. Lebold, *J. Org. Chem.*, 1990, **55**, 3853; (i) Y. Auberson and P. Vogel, *Tetrahedron*, 1990, **46**, 7019; (j) A. Chen, I. Savage, E. J. Thomas and P. D. Wilson, *Tetrahedron Lett.*, 1993, **34**, 6769; (k) N. Chida, K. Koizumi, K. Kitada, C. Yokoyama and S. Ogawa, *Chem. Commun.*, 1994, 111; (l) A. Dondoni, F. Junquera, F. L. Merchan, P. Merino and T. Tejero, *Tetrahedron Lett.*, 1994, **35**, 9439; (m) A. Dondoni, F. Junquera, F. L. Merchan, P. Merino and T. Tejero, *Chem. Commun.*, 1995, 2127; (n) B. M. Trost and Z. Shi, *J. Am. Chem. Soc.*, 1996, **118**, 3037; (o) K. Kato, C. Y. Chen and H. Akita, *Synthesis*, 1998, 1527; (p) A. K. Ghosh and Y. Wang, *J. Org. Chem.*, 1999, **64**, 2789; (q) K. M. K. Kutterer and G. Just, *Heterocycles*, 1999, **51**, 1409; (r) A. Chen, E. J. Thomas and P. D. Wilson, *J. Chem. Soc., Perkin Trans. 1*, 1999, 3305; (s) K. Uchida, K. Kato, K. Yamaguchi and H. Akita, *Heterocycles*, 2000, **53**, 2253; (t) C. Dehoux, L. Gorrichon and M. Baltas, *Eur. J. Org. Chem.*, 2001, 1105; (u) J. D. More and N. S. Finney, *Synlett*, 2003, 1307; (v) A. Plant, P. Thompson and D. M. Williams, *J. Org. Chem.*, 2008, **73**, 3714; (w) T. Nishiyama, T. Kajimoto, S. S. Mohile, N. Hayama, T. Otsuda, M. Ozeki and M. Node, *Tetrahedron: Asymmetry*, 2009, **20**, 230.
- 13 S. Cicchi, A. Goti, A. Brandi and A. Guarna, *Tetrahedron Lett.*, 1990, **31**, 3351.
- 14 R. Sakai, H. Kamiya, M. Murata and K. Shimamoto, *J. Am. Chem. Soc.*, 1997, **119**, 4112.
- 15 For total synthesis of dysiherbaine, see: (a) B. B. Snider and N. A. Hawryluk, *Org. Lett.*, 2000, **2**, 635; (b) M. Sasaki, T. Koike, R. Sakai and K. Tachibana, *Tetrahedron Lett.*, 2000, **41**, 3923; (c) H. Masaki, J. Maeyama, K. Kamada, T. Esumi, Y. Iwabuchi and S. Hatakeyama, *J. Am. Chem. Soc.*, 2000, **122**, 5216; (d) D. Phillips and A. R. Chamberlin, *J. Org. Chem.*, 2002, **67**, 3194; (e) M. Sasaki, N. Akiyama, K. Tsubone, M. Shoji, M. Oikawa and R. Sakai, *Tetrahedron Lett.*, 2007, **48**, 5697; (f) K. Takahashi, T. Matsumura, J. Ishihara and S. Hatakeyama, *Chem. Commun.*, 2007, 4158; (g) M. Sasaki, K. Tsubone, K. Aoki, N. Akiyama, M. Shoji, M. Oikawa, R. Sakai and K. Shimamoto, *J. Org. Chem.*, 2008, **73**, 264.
- 16 For formal synthesis and synthetic studies of dysiherbaine, see: (a) M. Sasaki, T. Maruyama, R. Sakai and K. Tachibana, *Tetrahedron Lett.*, 1999, **40**, 3195; (b) T. Naito, J. S. Nair, A. Nishiki, K. Yamashita and T. Kiguchi, *Heterocycles*, 2000, **53**, 2611; (c) J. Huang, K. Xu and T. Loh, *Synthesis*, 2003, 755; (d) O. Miyata, R. Iba, J. Hashimoto and T. Naito, *Org. Biomol. Chem.*, 2003, **1**, 772; (e) S. H. Kang and Y. M. Lee, *Synlett*, 2003, 993; (f) J. L. Cohen and A. R. Chamberlin, *Tetrahedron Lett.*, 2007, **48**, 2533; (g) R. Fernandez de la Pradilla, N. Lwoff and A. Viso, *Tetrahedron Lett.*, 2007, **48**, 8141.
- 17 For *N*-methylation using the HCHO-Et₃SiH/CF₃CO₂H sequence, see: J. Auerbach, M. Zamore and S. M. Weinreb, *J. Org. Chem.*, 1976, **41**, 725.